Abstract
The optimal time to initiate antiretroviral therapy (ART) in patients presenting with HIV-associated tuberculosis has been a controversial issue. Early initiation of ART may be complicated by high pill burden, overlapping drug toxicities, and an increased risk of immune reconstitution inflammatory syndrome. Delayed initiation of ART may result in progressive immune decline, HIV-associated complications and death. Retrospective studies of HIV/TB coinfected patients suggested that initiation of ART during TB treatment might be beneficial. Emerging evidence from recent randomised controlled trials supports early ART initiation in HIV/TB patients with advanced immunosuppression, apart from those presenting with tuberculous meningitis. However, current guidelines for antiretroviral therapy vary in their recommendations for timing of ART initiation in HIV-associated TB.
Keywords: Antiretroviral therapy, HIV, initiation, timing, tuberculosis, when to start.
Current Respiratory Medicine Reviews
Title:When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis
Volume: 9 Issue: 3
Author(s): Mili E. Torok
Affiliation:
Keywords: Antiretroviral therapy, HIV, initiation, timing, tuberculosis, when to start.
Abstract: The optimal time to initiate antiretroviral therapy (ART) in patients presenting with HIV-associated tuberculosis has been a controversial issue. Early initiation of ART may be complicated by high pill burden, overlapping drug toxicities, and an increased risk of immune reconstitution inflammatory syndrome. Delayed initiation of ART may result in progressive immune decline, HIV-associated complications and death. Retrospective studies of HIV/TB coinfected patients suggested that initiation of ART during TB treatment might be beneficial. Emerging evidence from recent randomised controlled trials supports early ART initiation in HIV/TB patients with advanced immunosuppression, apart from those presenting with tuberculous meningitis. However, current guidelines for antiretroviral therapy vary in their recommendations for timing of ART initiation in HIV-associated TB.
Export Options
About this article
Cite this article as:
Torok E. Mili, When to Start Antiretroviral Therapy in HIV-Associated Tuberculosis, Current Respiratory Medicine Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573398X113099990016
DOI https://dx.doi.org/10.2174/1573398X113099990016 |
Print ISSN 1573-398X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6387 |
Call for Papers in Thematic Issues
Exposure to PM2.5 components is associated with respiratory diseases
Through continuous research on the relationship between risk factors and health, it has been found that air pollution, especially atmospheric particulate matter pollution, has become one of the main sources of global disease burden. From 1990 to 2022, the concentration of atmospheric particulate matter pollution has increased by more than ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances and Challenges in Steroid Metabolomics for Biomarker Discovery
Current Medicinal Chemistry Gum-Chewing and Headache: An Underestimated Trigger of Headache Pain in Migraineurs?
CNS & Neurological Disorders - Drug Targets 1,2,3-Triazine Scaffold as a Potent Biologically Active Moiety: A Mini Review
Mini-Reviews in Medicinal Chemistry Update on Diagnostic and Treatment of Uncomplicated and Complicated Malaria in Adults and Selected Vulnerable Populations
Infectious Disorders - Drug Targets Tuberculosis: Challenges to Improve the Treatment
Current Clinical Pharmacology Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery Multiple Myeloma or Brucellosis: A Case Report
Infectious Disorders - Drug Targets Laboratory Diagnosis and Therapy of Invasive Fungal Infections
Current Drug Targets Inhibitors of Catechol-O-methyltransferase in the Treatment of Neurological Disorders
Central Nervous System Agents in Medicinal Chemistry Suicide Gene Therapy Mediated by the Herpes Simplex Virus Thymidine Kinase Gene / Ganciclovir System: Fifteen Years of Application
Current Gene Therapy Molecular Targets of Tannic Acid in Alzheimer's Disease
Current Alzheimer Research Seeing Genes at Work in the Living Brain with Non-Invasive Molecular Imaging
Current Gene Therapy COVID-19: The Significance of Platelets, Mitochondria, Vitamin D, Serotonin and the Gut Microbiota
Current Medicinal Chemistry Neurotrophic Factors in Combination: A Possible new Therapeutic Strategy to Influence Pathophysiology of Spinal Cord Injury and Repair Mechanisms
Current Pharmaceutical Design Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment
Current Cancer Therapy Reviews The Changing Face of HIV/AIDS in Treated Patients
Current HIV Research Smart Drug-Delivery Systems for Cancer Nanotherapy
Current Drug Targets Complexities of Glucuronidation Affecting In Vitro-In Vivo Extrapolation
Current Drug Metabolism Liposomes as Potential Carrier System for Targeted Delivery of Polyene Antibiotics
Recent Patents on Inflammation & Allergy Drug Discovery Formulation and Application of Biodegradable Nanoparticles Based Biopharmaceutical Delivery - An Efficient Delivery System
Current Pharmaceutical Design